Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO

Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO

Submitted by admin on April 13, 2021 - 10:24am
Source: 
Fierce Biotech
News Tags: 
Recursion Pharmaceuticals
IPOs
artificial intelligence
Headline: 
Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO
snippet: 

Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation.

Do Not Allow Advertisers to Use My Personal information